K-numberK242758
Device nameAtrauman® Ag
ApplicantHartmann USA, Inc.
Product codeFRO
Device classClass U
Decision dateDec 9, 2024
DecisionSubstantially Equivalent
Regulation
AI Summary extracted from FDA summary PDF · never regenerated
Intended use

Atrauman® Ag is a non-adherent, silver-impregnated antimicrobial wound dressing that maintains a moist wound environment. It consists of a meshed hydrophobic polyamide textile coated with metallic silver (2.1 mg/sq inch) combined with a hydrophilic triglyceride matrix. It is indicated for moderately exuding wounds including pressure wounds, venous leg ulcers, diabetic ulcers, partial thickness burns, skin graft donor sites, surgical wounds, and abrasions.

Technological characteristics

Both Atrauman® Ag and the predicate (UrgoTul Ag) share a non-adherent contact layer of hydrophobic polyamide mesh and incorporate silver for antibacterial properties within a hydrophilic impregnated matrix to maintain moist wound environment and absorb exudate. The key difference is that Atrauman Ag fibers are coated with elemental silver, whereas UrgoTul Ag uses silver sulfate in the matrix applied to the polyamide mesh with other ingredients.

Test standards cited

ISO 10993-1 (biocompatibility), ISO 10993-5:2009 (cytotoxicity), ISO 10993-10:2021 (sensitization), ISO 10993-23:2021 (irritation/intracutaneous reactivity), ISO 10993-11:2017 (pyrogenicity and systemic toxicity), ISO 10993-6:2016 (implantation), EN ISO 11137 series (radiation sterilization), EN ISO 11737 series (microbiological methods), ASTM D4169 (transport testing), and ANSI/AAMI ST72:2019 (bacterial endotoxins).

Substantial equivalence argument

Both devices have identical product codes (FRO, unclassified) and nearly identical indications for moderately exuding wounds. Functionally, they are equivalent: non-adherent contact layer, silver-based antibacterial mechanism, hydrophilic matrix for moisture management, and 7-day antimicrobial effectiveness. The differences in silver form (elemental vs. sulfate) and indications (UrgoTul supports graft sites; Atrauman does not yet) do not raise new safety or effectiveness questions. Performance testing demonstrates Atrauman meets applicable biocompatibility and sterilization standards equivalent to predicate performance.

Extracted by AI from the official FDA summary PDF →
Source

View the full FDA submission: accessdata.fda.gov

Researching this as a predicate?
Want a transparent AI-ranking score, AI-discovered related predicates, ongoing safety and warning-letter monitoring, full predicate chain lineage, and a drafted SE rationale — all saved to your own project? That's what an account adds.
Start free trial →

Everything you need for a 510(k) submission. Nothing you don't.

14-day free trial. No setup. Cancel anytime.

Start free trial →
Building an AI or ML-enabled device? Predicate search, PCCP tracking, and AI-specific FDA intelligence — built exclusively for AI/ML devices. Try AIFDA Intel →